Table 2.
Summary of new starts for first‐ through seventh‐lines of therapy included in the current analyses; patients with psoriasis initiating new therapy during the registry
| Ustekinumab | Infliximab | Adalimumab | Etanercept | Total | |
|---|---|---|---|---|---|
| New therapy starts, N | 1833 | 327 | 1303 | 537 | 4000 |
| First‐line therapya | 361 (19.7) | 63 (19.3) | 402 (30.9) | 289 (53.8) | 1115 |
| Second‐line therapy | 566 (30.9) | 93 (28.4) | 622 (47.7) | 155 (28.9) | 1436 |
| Third‐line therapy | 551 (30.1) | 103 (31.5) | 197 (15.1) | 71 (13.2) | 922 |
| Fourth‐line therapy | 248 (13.5) | 49 (15.0) | 71 (5.4) | 16 (3.0) | 384 |
| Fifth‐line therapy | 84 (4.6) | 14 (4.3) | 9 (0.7) | 6 (1.1) | 113 |
| Sixth‐line therapy | 21 (1.1) | 5 (1.5) | 2 (0.2) | 0 | 28 |
| Seventh‐line therapy | 2 (0.1) | 0 | 0 | 0 | 2 |
Data are presented as number of patients (%).
a
For lines of therapy beyond first‐line, the prior biologic may have been any of the four biologics included in these analyses or other biologics not approved for psoriasis (golimumab), those no longer available for treating psoriasis (efalizumab and alefacept) or those received via participation in a clinical study but not available for treatment of psoriasis (briakinumab).